Clinical trial for Esophageal Cancer
Official title Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
ClinicalTrials.gov ID: NCT06429839
What this study is testing
What is Nimotuzumab with chemoradiotherapy?
An investigational combination of an injectable antibody, chemotherapy, and radiotherapy being studied for esophageal cancer. Nimotuzumab is designed to target the EGFR protein on cancer cells.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if adding nimotuzumab improves surgery rates, tumor response, and safety when combined with chemotherapy and radiation.
- Who it's for
- Older adults or those with poor nutrition who have advanced esophageal squamous cell cancer that cannot be removed by surgery.
- What's involved
- Participants receive weekly nimotuzumab (800 mg), a chemotherapy drug called S‑1, and radiation therapy, with regular medical visits and tests to monitor progress and side‑effects.
- Time commitment
- The trial lasts about 6 months, with frequent clinic visits for treatment and monitoring throughout the course.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Histologically confirmed esophageal squamous cell carcinoma.
- No previous treatment for the esophageal carcinoma.
- KPS score ≥70.
- NRS-2002 score≥2.
- Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g/L ; absolute neutrophil count (NEUT)≥1.5×109/L
You likely can't join if
- Previous treatment of the esophageal cancer with surgery, radiation, or chemotherapy.
- Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ...
- At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal...
- There are active infections, such as active tuberculosis and hepatitis
- There are contraindications to targeted therapy.
The study team makes the final eligibility decision.
Where it is enrolling
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Beijing, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.